IP Library Granted Patent US 7,060,800
Granted Patent B2
US 7,060,800 · App. 09/949,192 · Granted Jun 13, 2006

Antibodies binding the TNF related protein, TNF-X

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,060,800
App. No.
09/949,192
Granted
Jun 13, 2006
Kind
B2
Abstract

Nucleic acids encoding mammalian, e.g., primate or rodent, genes, purified proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are provided.

Claims (30)

1. An isolated antibody or antigen binding fragment thereof, which specifically binds to a polypeptide of SEQ ID NO: 9.

2. The isolated antibody or antigen binding fragment thereof of claim 1 , wherein said antibody or antigen binding fragment thereof, is in a container.

3. The isolated antibody or antigen binding fragment thereof of claim 1 , wherein said antibody or antigen binding fragment thereof, is from a human.

4. The isolated antibody or antigen binding fragment thereof of claim 1 , wherein said antibody or antigen binding fragment thereof, is a Fv, Fab, or Fab 2 fragment.

5. The isolated antibody or antigen binding fragment thereof of claim 1 , wherein said antibody or antigen binding fragment thereof, is conjugated to another chemical moiety.

6. The isolated antibody or antigen binding fragment thereof of claim 1 , wherein said antibody or antigen binding fragment thereof, is generated using a recombinant polypeptide of SEQ ID NO:9.

7. The isolated antibody or antigen binding fragment thereof of claim 1 , wherein said antibody or antigen binding fragment thereof, is generated using a purified polypeptide of SEQ ID NO:9.

8. The isolated antibody or antigen binding fragment thereof of claim 1 , wherein said antibody or antigen binding fragment thereof, is:

a) is a polyclonal antibody;

b) a monoclonal antibody;

c) a humanized antibody; or

d) a chimeric antibody.

9. The isolated antibody or antigen binding fragment thereof of claim 1 , wherein said antibody or antigen binding fragment thereof, binds to a denatured polypeptide of SEQ ID NO:9.

10. The isolated antibody or antigen binding fragment thereof of claim 1 , wherein said antibody or antigen binding fragment thereof, exhibits a K d to a polypeptide of SEQ ID NO: 9 of at least 30 μM.

11. The isolated antibody or antigen binding fragment thereof of claim 1 , wherein said antibody or antigen binding fragment thereof, is attached to a solid substrate.

12. The isolated antibody or antigen binding fragment thereof of claim 1 , wherein said substrate is a bead or plastic membrane.

13. The isolated antibody or antigen binding fragment thereof of claim 1 , wherein said antibody or antigen binding fragment thereof, is detectably labeled.

14. A kit comprising said isolated antibody or antigen binding fragment thereof, of claim 1 , and:

a) a compartment comprising said antibody or antigen binding fragment thereof; or

b) instructions for use or disposal reagents in said kit.

15. A method of producing the isolated antibody or antigen binding compound thereof of claim 1 , comprising:

a) immunizing a mammalian host with said polypeptide; or

b) selecting for a phage display library for those phage which bind to said polypeptide.

16. The isolated antibody or antigen binding fragment thereof of claim 1 , wherein said antibody or antigen binding fragment thereof, is in a sterile composition.

17. The isolated antibody or antigen binding fragment thereof of claim 16 , wherein said label is a radioactive or fluorescent label.

18. A composition comprising:

a) said isolated antibody or antigen binding fragment thereof of claim 1 , wherein said antibody or antigen binding fragment thereof, is sterile; or

b) said antibody or antigen binding fragment thereof, of claim 1 , and a carrier.

19. The composition of claim 18 , wherein said carrier is an aqueous compound is water, saline, or buffer.

20. The composition of claim 18 , wherein said carrier is formulated for oral, rectal, nasal, topical, or parenteral administration.

Assignments (1)
CHANGE OF NAME Recorded Aug 30, 2012
From: SCHERING CORPORATION
To: MERCK SHARP & DOHME CORP.
Reel/Frame 028884/0151 →